Cet anticorp PDCD1 (Nivolumab Biosimilar) est non-conjugé
Application
Flow Cytometry (FACS), In vivo Studies (in vivo)
Fonction
Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody
Specificité
The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Attributs du produit
Recombinant Humanized IgG4 Monoclonal Antibody.
Purification
Protein A affinity column
Pureté
> 95% by SDS-PAGE under reducing conditions and HPLC.
Stérilité
0.2 μm filtered
niveau d'endotoxine
< 1 EU per 1 mg of the protein by the LAL method.
Immunogène
The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Agent conservateur
Without preservative
Conseil sur la manipulation
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Stock
-20 °C
Stockage commentaire
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.
PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).
Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.
The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.